Skip to Main Content

scPharmaceuticals Inc. Common Stock

SCPH Real Time Price USD
2.38
+0.03
(1.27%)
As of today at 11:40 UTC-04:00
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of SCPH by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
SCPH Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
SCPH Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
SCPH Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Whales3.333333333New1Increased5Held2Decreased1Closed1

Quarterly net insider trading by SCPH's directors and management

2024Q22024Q32024Q42025Q12025Q20100k200k300k400k500k
Net Shares Purchased by Insiders

Government lobbying spending instances

  • $12,500 Apr 15, 2025 Issue: Medicare/Medicaid Health Issues
  • $12,500 Jan 10, 2025 Issue: Medicare/Medicaid Health Issues
  • $12,500 Oct 17, 2024 Issue: Health Issues Medicare/Medicaid
  • $12,500 Jul 15, 2024 Issue: Health Issues Medicare/Medicaid
  • $12,500 Apr 17, 2024 Issue: Health Issues Medicare/Medicaid

Estimated quarterly lobbying spending

20242025010k20k30k40k50k
Q4Q3Q2Q1Lobbying Amount

SCPH Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
SCPH Income Statement
SCPH Balance Sheet
SCPH Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same Jul. 30, 2024
  • Patent Title: Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same Jun. 04, 2024
  • Patent Title: Concentrated liquid pharmaceutical formulations of furosemide Feb. 07, 2023
  • Patent Title: Concentrated liquid pharmaceutical formulations of furosemide Jan. 24, 2023
  • Patent Title: Concentrated liquid pharmaceutical formulations of furosemide Nov. 15, 2022
  • Patent Title: Pharmaceutical formulations for subcutaneous administration of furosemide Sep. 06, 2022
  • Patent Title: Pharmaceutical formulations for subcutaneous administration of furosemide Apr. 30, 2019
  • Patent Title: Pharmaceutical formulations for subcutaneous administration of furosemide Feb. 06, 2018
Government Contracts

Estimated quarterly amount awarded from public contracts

202302k4k6k8k10k12k14k
Q4Q3Q2Q1Government Contracts Amount
SCPH News

Recent insights relating to SCPH

Quiver QuantitativeNew Lobbying Disclosure: SCPHARMACEUTICALS INC. ($SCPH) disclosed spending $12500 lobbying (Medicare reimbursement of pharmaceuticals )Article Thumbnail
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly EarningsArticle Thumbnail
scPharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results with Major FDA Approval for FUROSCIXArticle Thumbnail
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and MoreArticle Thumbnail
Lobbying Update: $12,500 of SCPHARMACEUTICALS INC. lobbying was just disclosedArticle Thumbnail
Quiver QuantitativeNew Lobbying Disclosure: SCPHARMACEUTICALS INC. ($SCPH) disclosed spending $12500 lobbying (Medicare reimbursement of pharmaceuticals )Article Thumbnail
scPharmaceuticals Inc. Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results, Projecting Significant Revenue GrowthArticle Thumbnail
Quiver QuantitativeNew Lobbying Disclosure: SCPHARMACEUTICALS INC. ($SCPH) disclosed spending $12500 lobbying (general issues of interest to pharmaceutical companies )Article Thumbnail
Quiver QuantitativeNew Lobbying Disclosure: SCPHARMACEUTICALS, INC. ($SCPH) disclosed spending $12500 lobbying (general issues of interest to pharmaceutical companies )Article Thumbnail
Quiver QuantitativeNew Lobbying Disclosure: SCPHARMACEUTICALS, INC. ($SCPH) disclosed spending $12500 lobbying (general issues of interest to pharmaceutical companies )Article Thumbnail
Quiver QuantitativeNew Lobbying Disclosure: SCPHARMACEUTICALS, INC. ($SCPH) disclosed lobbying (MMM - Medicare reimbursement of pharmaceuticals HCR - General Issues of interest to pharmaceutical companies VET - VA coverage of pharmaceuticals )Article Thumbnail
CNBC Recommendations

Recent picks made for SCPH stock on CNBC

Quiver Logo

No CNBC Picks data for this ticker

CNBC Stock Picks Dashboard
Top ETF Holders

ETFs with the largest estimated holdings in SCPH

SCPH Analyst Ratings

SCPH Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
SCPH Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $SCPH stock a Buy, Sell, or Hold?

  • What is the price target for $SCPH stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

SCPH Top Shareholders
Shareholder
Shares Held
SCPH Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $SCPH stock?

  • Who owns the most shares of $SCPH stock?

  • What funds own $SCPH stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

SCPH Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view SCPH Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Bull Case vs Bear Case data is only available to Quiver Premium subscribers.

Back To Top